Skip to content
    Soleus Capital logo

    Soleus Capital

    Greenwich, Connecticut, United StatesFounded 2018
    soleuscapital.comLinkedIn
    Biotech & Life SciencesHealthcare

    Soleus Capital is a healthcare investment firm focused on the innovative areas of life sciences, including biotech, medtech, diagnostics, and genomics. Founded in 2018 and based in Greenwich, CT, the firm manages hedge, private equity, and credit funds primarily focused on healthcare-related companies across the United States.

    51% of their portfolio is in Biotech & Life Sciences. Deal activity decreased year-over-year (3 deals in the last 12 months vs 5 prior). Average disclosed round size is $118.2M (across 50 rounds with reported amounts).

    Find people at Soleus Capital on Goldilocks AI

    Portfolio

    42

    Fund Size

    —

    Top Stage

    Series C

    Last 12 Mo

    3

    Team

    SM

    Steve Musumeci

    Founding Partner

    BL

    Benjamin Lund

    Partner

    DC

    David Canner

    Partner

    BW

    Ben Wessner

    Principal

    CM

    Connor McDermott

    Analyst

    RB

    Ryan Berry

    Biotech Investor

    Portfolio Breakdown

    Stage Distribution

    Sector Distribution

    Investment Activity

    DealsAvg Round Size

    Portfolio

    59 investments
    CompanyRoundAmountDate
    PParabilisSeries F$305MSep 2026
    BBridge To LifeSeries C$110MAug 2026
    BBridge To LifeBridge—Aug 2026
    Crystalys Therapeutics Inc logoCrystalys Therapeutics IncSeries B$130MJul 2026
    Parabilis Medicines logoParabilis MedicinesSeries F$305MJan 2026
    PParabilisSeries F$305MJan 2026
    Crescent Biopharma logoCrescent BiopharmaGrowth$200MJun 2025
    Pillar Biosciences logoPillar BiosciencesSeries B$34.5MMay 2025
    Neurona Therapeutics logoNeurona TherapeuticsUnknown$102MApr 2025
    Abcuro, Inc. logoAbcuro, Inc.Series C$200MFeb 2025
    Star Therapeutics logoStar TherapeuticsSeries D$125MJan 2025
    OrganOx logoOrganOxUnknown$142MJan 2025
    Neurona logoNeuronaSeries A$102MJan 2025
    Pillar Biosciences logoPillar BiosciencesSeries C$64MJan 2025
    Blue Earth Therapeutics Ltd logoBlue Earth Therapeutics LtdSeries A$76.5MOct 2024
    Parse Biosciences logoParse BiosciencesSeries C—Dec 2023
    COMPASS Pathways logoCOMPASS PathwaysSeries A$285MAug 2023
    Parse Biosciences logoParse BiosciencesSeries C$50MJan 2023
    Beta Bionics logoBeta BionicsSeries C$57MFeb 2022
    RayzeBio logoRayzeBioSeries D$160MJan 2022
    Freenome logoFreenomeSeries D$300MDec 2021
    AAntios Therapeutics, Inc.Series B$75MNov 2021
    AAntios Therapeutics, Inc.Series A$75MNov 2021
    Obsidian Therapeutics logoObsidian TherapeuticsSeries B$115MSep 2021
    BBridge To LifeSeries A$56MAug 2021
    Page 1 of 3

    Top Co-Investors

    RA Capital Management21 shared
    Cormorant Asset Management16 shared
    Perceptive Advisors13 shared
    Pontifax9 shared
    Logos Capital9 shared
    HBM Healthcare Investments9 shared
    Novo Holdings A/S8 shared
    Redmile Group8 shared
    Farallon Capital Management7 shared
    Samsara BioCapital7 shared
    RTW Investments, LP6 shared
    Sofinnova Partners6 shared
    Frazier Life Sciences6 shared
    OrbiMed6 shared
    Foresite Capital6 shared
    Novo Capital6 shared
    LifeSci Venture Partners5 shared
    Adage Capital Management5 shared
    Sixty Degree Capital5 shared
    Schroders Capital5 shared

    Last updated: 7 October 2026